Orodax (Solifenacin Succinate)

Solifenacin succinate, the active ingredient in Orodax, is a muscarinic receptor antagonist presented as a oral tablet for oral use. It is used to manage symptoms of an overactive bladder in adults. GNH USA supplies Orodax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Orodax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orodax is a bladder‑control medication that works on the urinary storage pathway.

- Overactive bladder: Improves urgency, frequency and nocturia. - Neurogenic detrusor overactivity: Reduces involuntary bladder contractions. - Detrusor instability: Helps stabilize bladder muscle activity.

Side effects reported with solifenacin are generally mild to moderate and vary by individual.

Common Side Effects: - Dry mouth: Reduced salivation leading to a feeling of thirst. - Constipation: Slowed intestinal transit. - Blurred vision: Temporary visual disturbances. - Urinary retention: Difficulty initiating urination. - Headache: Mild to moderate head pain. - Dizziness: Light‑headed sensation.

Serious or Rare Side Effects: - Severe urinary retention requiring catheterisation. - Acute angle‑closure glaucoma. - Allergic reactions: Rash, itching, swelling or anaphylaxis. - Tachycardia: Rapid heart rate. - Hepatic enzyme elevation. - Persistent severe constipation.

When prescribing Orodax, clinicians should consider several safety aspects.

- Renal impairment: Dose adjustment may be needed. - Hepatic impairment: Use with caution. - Elderly patients: Monitor for anticholinergic burden. - Concomitant anticholinergics: Assess cumulative effect. - Narrow‑angle glaucoma: Contra‑indicated. - Store at ambient temperature: Keep in original packaging, protect from moisture.

Orodax may interact with other medicines that influence cholinergic pathways.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: May increase solifenacin levels. - P‑Mediated P‑R   .

Moderate   t  t .